Biotech & Pharma SPACs

The Biotech and Pharma sector currently counts five active SPACs, with two vehicles still searching for acquisition targets and three that have announced definitive business combinations. The cohort's median days-to-expiration stands at 381 days, indicating that most vehicles retain meaningful runway to close pending deals or surface new ones. Healthcare-focused blank-check companies have drawn specialist sponsors seeking to bring clinical-stage and commercial-stage businesses to public markets as an alternative to the traditional IPO route. The sector's regulatory complexity and extended diligence timelines have historically pushed deal cycles beyond those seen in most other SPAC verticals. For complete sponsor profiles, pipeline details, and real-time deal status on every Biotech and Pharma SPAC, sign up for full data access at SpacDesk.

Active = status not liquidated/closed/withdrawn. Trust size reflects declared trust at IPO. Industry classification based on sponsor focus area and target company sector.